| Literature DB >> 35701428 |
Russell H Tobe1,2,3, Anna MacKay-Brandt4, Ryan Lim4, Melissa Kramer4, Melissa M Breland4, Lucia Tu4, Yiwen Tian4, Kristin Dietz Trautman4, Caixia Hu4, Raj Sangoi4, Lindsay Alexander5, Vilma Gabbay4,6, F Xavier Castellanos4,7, Bennett L Leventhal8, R Cameron Craddock9, Stanley J Colcombe4,10, Alexandre R Franco4,5,10, Michael P Milham11,12.
Abstract
Most psychiatric disorders are chronic, associated with high levels of disability and distress, and present during pediatric development. Scientific innovation increasingly allows researchers to probe brain-behavior relationships in the developing human. As a result, ambitions to (1) establish normative pediatric brain development trajectories akin to growth curves, (2) characterize reliable metrics for distinguishing illness, and (3) develop clinically useful tools to assist in the diagnosis and management of mental health and learning disorders have gained significant momentum. To this end, the NKI-Rockland Sample initiative was created to probe lifespan development as a large-scale multimodal dataset. The NKI-Rockland Sample Longitudinal Discovery of Brain Development Trajectories substudy (N = 369) is a 24- to 30-month multi-cohort longitudinal pediatric investigation (ages 6.0-17.0 at enrollment) carried out in a community-ascertained sample. Data include psychiatric diagnostic, medical, behavioral, and cognitive phenotyping, as well as multimodal brain imaging (resting fMRI, diffusion MRI, morphometric MRI, arterial spin labeling), genetics, and actigraphy. Herein, we present the rationale, design, and implementation of the Longitudinal Discovery of Brain Development Trajectories protocol.Entities:
Mesh:
Year: 2022 PMID: 35701428 PMCID: PMC9197863 DOI: 10.1038/s41597-022-01329-y
Source DB: PubMed Journal: Sci Data ISSN: 2052-4463 Impact factor: 8.501
Fig. 1Participant enrollment and attrition. (a) Adapted CONSORT diagram demonstrating group level attrition by longitudinal follow-up track (either 0/12/24 month or 0/15/30 month follow-up) and characterization time-points, (b) Participant-level characterization time-point completion stratified by age at enrollment, females coded as red and males coded as blue, (c) Participant-level days to follow-up characterization visit from baseline, (d) Participant-level days to retest from most recent characterization visit. FLU1 = Follow-up Visit 1 (mid-point visit), FLU2 = Follow-up Visit 2 (final visit).
Participant inclusion and exclusion criteria.
| 1. Male or female ages 6.0–20.5 years (ages 6.0–17.9 at enrollment) |
| 2. Children who become adults during participation have capacity to understand and provide informed consent |
| 3. Children ages 6.0–17.9 with capacity to sign assent and parent/guardian with capacity to sign informed consent |
| 4. Fluent in English |
| 5. Proof of Rockland County, Orange County, Bergen County, or Westchester County Residency |
| 1. Parents unable to provide developmental and/or biological family histories (e.g., some instances of adoption) |
| 2. Known intrauterine exposures capable of altering brain structure or function (teratogenic medications, any illicit drug use, smoking >1/2 pack per day or >2 alcoholic drinks per week during pregnancy), hyperbilirubinemia requiring transfusion or phototherapy >2 days, multiple birth, infant resuscitation by chest compression or intubation, birth weight <1500 gm or >4200 gm. |
| 3. Current height or weight <3rd percentile, or head circumference <3rd percentile by National Center for Health Statistics 2000 data. |
| 4. History of significant medical or neurological disorder with CNS implications (e.g., seizure disorder, CNS infection, malignancy, diabetes, systemic rheumatologic illness, muscular dystrophy, migraine or cluster headaches, sickle cell anemia, etc.), significant traumatic brain injury |
| 5. History of neonatal stroke |
| 6. Malignancy |
| 7. Hearing or visual impairment that prevents participation in study-related tasks. |
| 8. Current positive pregnancy test (for menarchal females) |
| 9. Current or past treatment for language disorders (except simple articulation disorders) |
| 10. History of clinically significant psychotic episode not attributable to a general medical condition or medication side effect |
| 11. History of Autism Spectrum Disorder |
| 12. Current suicidal/homicidal ideation |
| 13. History of treatment with the following psychotropic medications: antidepressants, neuroleptics, and mood stabilizers |
| 14. History of lifetime substance dependence requiring chemical replacement therapy |
| 15. History of substance dependence within in the last two years except nicotine and marijuana |
| 16. History of psychiatric hospitalization |
| 17. IQ < 70 |
| 18. Known neurodegenerative disorder |
| 19. First degree relatives with lifetime history of autism spectrum disorder, idiopathic intellectual disability, schizophrenia, psychotic disorder |
| 20. Contraindication for MRI scanning (mental implants, pacemakers, claustrophobia, metal foreign bodies or pregnancy) |
Complete protocol.
| Assessments/Procedures | Baseline Visit | Follow-Up Visit |
|---|---|---|
| Brain Injury Screening Questionnaire (BISQ)† | ✓ | ✓ |
| Child/Adult Satisfaction Questionnaire | ✓ | ✓ |
| Consent | ✓ | ✓ |
| Demographic Questionnaire | ✓ | ✓ |
| Demographics Supplement | ✓ | |
| Family History Questionnaire – Parent | ✓ | |
| Hollingshead Four-Factor Index of Socioeconomic Status (SES) | ✓ | |
| Medical History Questionnaire – Child† | ✓ | ✓ |
| Medications/Medical Conditions – Parent† | ✓ | ✓ |
| 6-Minute Bike Test | ✓ | ✓ |
| Actigraphy | ✓ | ✓ |
| Blood Draw | ✓ | ✓ |
| Cambridge-Hopkins Restless Legs Syndrome (CHRLS, 18+)† | ✓ | |
| Color Vision | ✓ | |
| Edinburgh Handedness Questionnaire (EHQ, 6–17)† | ✓ | |
| Grip Strength | ✓ | |
| Grooved Pegboard | ✓ | ✓ |
| International Physical Activity Questionnaire (IPAQ, 15+)† | ✓ | ✓ |
| Pittsburgh Sleep Quality Index (PSQI, 13+)† | ✓ | ✓ |
| Tanner Scale | ✓ | ✓ |
| Weight/Height, Vital Signs, Hip/Waist Measurement | ✓ | ✓ |
| Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version (KSADS-PL, 6–17) | ✓ | ✓ |
| Structured Clinical Interview for DSM Disorders (SCID, 18+) | ✓ | |
| Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS, 6–17) | ✓ | ✓ |
| Vineland Adaptive Behavior Scales (VABS, 6–17) | ✓ | |
| Yale Global Tic Severity Scale (YGTSS, 6–17) | ✓ | ✓ |
| Attention Network Test (ANT) | ✓ | ✓ |
| Delis-Kaplan Executive Function System (D-KEFS) – Verbal Fluency (8+) | ✓ | ✓ |
| DKEFS – Trails (8+) | ✓ | ✓ |
| DKEFS – Design Fluency (8+) | ✓ | ✓ |
| DKEFS – Color-Word Interference Test (8+) | ✓ | ✓ |
| DKEFS – Tower (8+) | ✓ | ✓ |
| Digit Span | ✓ | ✓ |
| Penn Computerized Neurocognitive Battery (CNB) | ✓ | ✓ |
| Rey Auditory Verbal Learning Test (RAVLT; 8+) | ✓ | ✓ |
| Wechsler Abbreviated Scale of Intelligence-II (WASI) | ✓ | |
| Wechsler Individual Achievement Test-II (WIAT) | ✓ | |
| Magnetic Resonance Imaging (MRI) Session | ✓ | ✓ |
| Mock Scan | ✓ | |
| MRI-Questionnaire (MRIQ; 13+) | ✓ | ✓ |
| Urine Drug Test (11+) | ✓ | ✓ |
| Comprehensive Addiction Severity Index for Adolescents (CASI, 11+) | ✓ | ✓ |
| Fagerstrom Test for Nicotine Dependence (FTND, 18+) | ✓ | |
| Modified Fagerstrom Tolerance Questionnaire – Adolescents (FTQA, 13–17) | ✓ | ✓ |
| National Institute on Drug Abuse Questionnaire (NIDA, 11+) | ✓ | ✓ |
| Behavioral Indicator of Resiliency to Distress (BIRD)‡ | ✓ | ✓ |
| Dot Probe‡ | ✓ | ✓ |
| The High-Functioning Autism Spectrum Screening Questionnaire (ASSQ, 6–17)† | ✓ | ✓ |
| Adult Self-Report (ASR, 18+) | ✓ | |
| Adult Temperament Questionnaire (ATQ, 16+)† | ✓ | ✓ |
| Behavior Assessment System for Children 2nd Edition – Parent Rating Scale (BASC, 7–17) | ✓ | ✓ |
| Beck Depression Inventory (BDI, 18+) | ✓ | |
| Child Behavior Checklist (CBCL, 7–17) | ✓ | ✓ |
| CBCL-Adaptive Functioning (7–17) | ✓ | ✓ |
| Children’s Behavior Questionnaire Very Short Form (CBQ-VSF, 6–8)† | ✓ | ✓ |
| Children’s Depression Inventory 2 (CDI-2, 11–17) | ✓ | ✓ |
| Child Eating Behavior Questionnaire (CEBQ, 7–11)† | ✓ | ✓ |
| Cognitive Failures Questionnaire (CFQ, 16+)† | ✓ | ✓ |
| Connors 3rd Edition – Parent Short Form (6–17)† | ✓ | ✓ |
| Connors 3rd Edition – Self-Report Short Form (8–17)† | ✓ | ✓ |
| Early Adolescent Temperament Questionnaire (EATQ, 9–15)† | ✓ | ✓ |
| Eating Disorder Examination Questionnaire (EDEQ, 13+)† | ✓ | ✓ |
| Inventory of Callous-Unemotional Traits – Parent Version (ICU-P, 7–17)† | ✓ | ✓ |
| Inventory of Callous-Unemotional Traits – Youth Self Report (ICU-Y, 13+)† | ✓ | ✓ |
| Interpersonal Reactivity Index (IRI, 13+)† | ✓ | ✓ |
| Multidimensional Anxiety Scale for Children (MASC, 8–17)† | ✓ | ✓ |
| NEO Five Factor Inventory - 3 (NEO, 12–17)† | ✓ | |
| The 21-Item Peters | ✓ | ✓ |
| Phenotyping and eXposures (PhenX) Sex History Questionnaire (13+)† | ✓ | ✓ |
| Repetitive Behaviors Scale – Revised (RBS-R, 6–17)† | ✓ | ✓ |
| Sex Role Identity Scale (13+)† | ✓ | ✓ |
| Sexual Orientation Scale (13+)† | ✓ | ✓ |
| Social Responsiveness Scale-Parent Report (SRS, 7–17)† | ✓ | ✓ |
| State-Trait Anxiety Inventory (STAI, 18+)† | ✓ | |
| Strengths and Weaknesses of Attention-Deficit/Hyperactivity Disorder Symptoms and Normal Behavior Scale (SWAN, 6–17)† | ✓ | ✓ |
| Three-Factor Eating Questionnaire (TFEQ, 12+)† | ✓ | ✓ |
| Trauma Symptom Checklist for Children (TSC-C, 11–17) | ✓ | ✓ |
| Trauma Symptoms Checklist for Adults (TSC-40, 18+) | ✓ | |
| University of California at Los Angeles Posttraumatic Stress Disorder Reaction Index (UCLA-PTSD) Parent (6–17) | ✓ | ✓ |
| UCLA-PTSD Child (8–17) | ✓ | ✓ |
| UPPS-P Impulsive Behavior Scale (18+) | ✓ | |
| Youth Self-Report (YSR, 11–17) | ✓ | ✓ |
| YSR Adaptive Functioning (11–17) | ✓ | ✓ |
| Youth Risk Behavior Surveillance System Middle School/High School (YSRBS, 12+) | ✓ | ✓ |
†Can be completed as a home assessment.
‡Optional at follow-up based on time availability.
Sample baseline characterization schedule.
| Time (min) | Child Activity | Parent Activity |
|---|---|---|
| 25 | Height, weight, vitals, hip/waist measurements, blood draw, genetics, Tanner staging, color vision, grip strength, medications and medical conditions collected, urine drug test (ages 11+), urine pregnancy test (postmenarchal females) | Tanner Staging (for children under 12) |
| 15 | Break/Breakfast | MRI Safety Screener (repeated) |
| 80 | MRI/MRIQ | |
| 10 | Break | |
| 60 | Penn Computerized Neurocognitive Battery* | KSADS (Parent Interview), Hollingshead SES |
| 20 | KSADS (Child Interview) | Vineland Behavior Scale |
| 30 | Break/Lunch | |
| 120 | WASI, WIAT, DKEFS, RAVLT, Digit Span, Pegboard* | |
| 15 | Break | |
| 40 | Child onsite questionnaires | Parent onsite questionnaires |
| 30 | Attention Network Test | |
| 15 | Family History questionnaire | |
| 6 | 6-minute bike | |
| 10 | Satisfaction Survey (Ages 12+) | Satisfaction Survey |
*During the cognitive testing blocks, breaks were provided between tasks at rater discretion as deemed necessary.
Imaging Protocol.
| Scan Type | Time Acquisition (min:sec) | Slices | % FOV Phase | Resolution (mm) | matrix | TR (ms) | TE (ms) | Flip Angle (°) | Multi Band Accel | Phase Partial Fourier | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T1-weighted (MPRAGE) | 4 m:18 s | 176 | 96% | 1 × 1 × 1 | 256 × 256 | 1900 | 2.52 | 9 | N/A | off | TI (ms) = 900 |
| T2 FLAIR | 3 m:02 s | 44 | 75% | 1 × 1 × 3 | 256 × 192 | 900 | 106 | 180 | N/A | off | TI (ms) = 2500 |
| DTI | 5 m:43 s | 64 | 84.90% | 2 × 2 × 2 | 106 × 90 | 2400 | 87 | 90 | 4 | 6/8 | 128 directions; b = 1500 s/mm2; 9 b0 images |
| R-fMRI (m-645) | 9 m:46 s | 40 | 100% | 3 × 3 × 3 | 74 × 74 | 645 | 30 | 60 | 4 | off | |
| R-fMRI (mb-1400) | 9 m:45 s | 64 | 100% | 2 × 2 × 2 | 112 × 122 | 1400 | 30 | 65 | 4 | 6/8 | |
| R-fmri (sb) | 5 m:05 s | 38 | 100% | 3 × 3 × 3 | 72 × 72 | 2500 | 30 | 80 | sb | off | |
| Visual Checkerboard Stimulation (mb 645) | 2m41s | 40 | 100% | 3 × 3 × 3 | 74 × 74 | 645 | 30 | 60 | 4 | off | |
| Visual Checkerboard Stimulation (mb 1400) | 2m27s | 64 | 100% | 2 × 2 × 2 | 112 × 112 | 1400 | 30 | 64 | 4 | 6/8 | |
| Breath Holding | 4m30s | 64 | 100% | 2 × 2 × 2 | 112 × 112 | 1400 | 30 | 65 | 4 | 6/8 | |
| pCASL | 5m15s | 24 | 100% | 3.4 × 3.4 × 4.2 | 64 × 64 | 3800 | 17 | 90 | N/A | 7/8 | Label offset = 80 mm, post label delay = 1000 ms |
| T2 SPACE | 3m52s | 176 | 100% | 1 × 1 × 1 | 256 × 256 | 3200 | 305 | varies | N/A | off |
*iso – Isotropic, * mb – Multi Band, * sb – Single Band, * pCASL – Pseudo-Continuous Arterial Spin Labeling. Full printouts of the imaging protocols can be downloaded here: http://fcon_1000.projects.nitrc.org/indi/enhanced/mri_protocol.html.
Demography of the NKI-Rockland Sample Longitudinal Discovery of Brain Development Trajectories sub-study (enrollment years 2013-2017); the NKI-Rockland Sample (enrollment years 2011-2019); along with the 2009 Rockland County, New York State, and United States Census Data.
| NKI-Rockland Sample Longitudinal Discovery of Brain Development Trajectories | NKI-Rockland Sample | Rockland County | New York State | USA | |
|---|---|---|---|---|---|
| 351* | 1,610 | 300,173 | 19,541,453 | 309,529,237 | |
| N/A | N/A | 7.70% | 6.30% | 7% | |
| 100.00% | 26.15% | 27.70% | 22.60% | 24% | |
| N/A | 14.91% | 13.70% | 13.40% | 13% | |
| 45.01% | 59.38% | 50.50% | 51.40% | 51% | |
| 68.09% | 72.73% | 80.40% | 73.40% | 79.60% | |
| 18.80% | 17.27% | 11.40% | 17.20% | 13% | |
| 1.42% | 0.93% | 0.30% | 0.60% | 1% | |
| 7.69% | 5.59% | 6.30% | 7.10% | 5% | |
| 0.57% | 0.43% | 0.20% | 0.10% | 0% | |
| N/A† | N/A† | 1.40% | 1.60% | 2% | |
| 18.80% | 13.04% | 13.80% | 16.80% | 16% | |
| N/A† | N/A† | 19.10% | 20.40% | 11% | |
| 25.64% | 26.58%‡ | 29.90% | 28.00% | 18% | |
| N/A | 99.07% | 85.30% | 79.10% | 80% | |
| N/A | 62.41% | 37.50% | 27.40% | 24% | |
| 4.29 | 3.40 | 3.01 | 2.61 | 2.51 | |
| $75,000-$99,900 | $75,000-$99,900 | $84,076 | $55,980 | $52,029 | |
| N/A† | N/A† | $28,082 | $23,389 | $21,587 | |
| N/A† | N/A† | 10.40% | 13.70% | 13.20% |
*Of the 369 participants enrolled, 351 participants completed baseline demography.
†Several census variables were not replicated in the NKI-Rockland Sample: there was no participant option to identify two or more races or birth outside of the United States, and income was obtained as a range which could not be translated to per capita income or poverty thresholds.
‡Household language was added to the protocol February 2013 and, therefore, administered to a subgroup of NKI-Rockland Sample participants (N = 1,204).
§Participants aged 25 and older.
Fig. 2Age, sex, and diagnostic distribution of participants. (a) Age and sex distribution of participants. (b) Frequency of diagnoses given to participants during the baseline characterization visit. Participants could receive more than one diagnosis. Diagnostic data for this figure represent the ‘consensus diagnosis’ factoring all data collected during the protocol visit, including the K-SADS, medical history, and clinically-relevant measures. Females are coded as red, and males are coded as blue.
Fig. 3Distribution of general intellectual ability, academic achievement, and broad mental health measures. Participant IQ was estimated using the WASI-II (top row left to right: Verbal Comprehension Index Composite; Perceptual Reasoning Index Composite; and Full-Scale IQ Composite). Academic Achievement as measured by WIAT-II (middle row left to right: Word Reading; Numerical Operations; and Spelling Standard Scores. Mental Health as measured by CBCL (bottom row left to right: CBCL Total Score; Internalizing Problems Scale; and Externalizing Problems Scale). Data are represented for all participants at baseline.
Fig. 6Physical measures distribution with age. (a) Time (in seconds) to completion of the Purdue Pegboard task and (b) kilogram-force Grip Strength with age are represented for all participants (age 6–17) with females coded as red and males coded as blue. Color shading degree indicates Tanner stage. Box plots by Tanner stage for (c) time to completion of Purdue Pegboard task and (d) kilogram-force Grip Strength are represented for males and females with * indicating statistical separation between males and females at that Tanner stage (p < 0.05).
Fig. 4Distribution of attention ratings. Total CBCL Attention subdomain distribution compared to total SWAN distribution (left column). Distributions of Conners Inattention compared to SWAN Inattention (middle column) and Conners Hyperactivity compared to SWAN Hyperactivity (right column). The distribution of each scale was tested for normality using the Shapiro-Wilk test. Finally, Pearson (r) and Spearman (p) correlations between the SWAN and Conners are represented for both the hyperactivity and inattention subscales for all participants, those with SWAN > = 0, and participants with SWAN <0.
Fig. 5Raw and standardized results of the D-KEFS Color-Word Interference Test. From left to right, D-KEFS Color Word Interference Test Color Naming; Inhibition; and Switching Conditions are represented by age for participants (ages 8+) with females coded as red and males coded as blue. Individual lines demonstrate participant-level longitudinal change. Raw scores and error are reflected in Row 1 while standard scores and error are reflected in Row 2. Larger circle sizes indicate more errors.
Fig. 7Correlation matrix of phenotypic measures. Heatmap depicting correlations between a broad sampling of behavioral, cognitive, and physical measures. Correlation values represented with color coding survived multiple comparisons correction (false discovery rate; q < 0.05). BMI, Body Mass Index; WASI, Wechsler Abbreviated Scale of Intelligence-II; VCI, Verbal Comprehension Index; PRI, Perceptual Reasoning Index; WIAT, Wechsler Individual Achievement Test-II; Read, Word Reading; Num, Numerical Operations; Spell, Spelling; CBCL, Child Behavior Checklist; Int, Internalizing Subscale; Ext, Externalizing Scale; SWAN; Strengths and Weaknesses of Attention-Deficit/Hyperactivity Disorder Symptoms and Normal Behavior Scale; Hyp, Hyperactivity Subscale; SRS, Social Responsiveness Scale; MASC, Multidimensional Anxiety Scale for Children; ICU-P, Inventory of Callous-Unemotional Traits – Parent Version; Grip, Grip Strength; Hemo, Serum Hemoglobin; Tanner, Tanner Stage; NIDA, National Institute on Drug Abuse Questionnaire; Corr, Correlation.
Fig. 8Development curves for intracranial, gray matter, white matter, cerebral spinal fluid, and ventricular volume, mean cortical thickness, and mean surface area. Data from all participants were included in these plots, independent of data quality.
Fig. 9Quality control measures for structural scans. (a) Average Braindr scores per age group. (b) Correspondence between Braindr and Euler number. (c) Receiver operating characteristic (ROC) curve showing the predictability of the Euler number to identify passed (braindr> = 0.5) or failed (braindr < 0.5) structural images.
Fig. 10Distribution of age and quality control measures for structural scans (Euler Number) and mean Framewise Displacement (FD) for the Diffusion Scans (DTI) and functional scans. BH-1400: Breath holding task with TR = 1400 ms; CB-1400: Checkerboard stimulation task with TR = 1400 ms; pCASL: pseudo-Continuous Arterial Spin Labeling scan; Rest-1400: Multiband resting state scan with TR = 1400 ms; Rest-645: Multiband resting state scan with TR = 645 ms; Rest-CAP: Single band resting state scan with TR = 2500 ms. Correlations between quality control measures are calculated across the whole sample (text in black), or within sex group (red: females; blue: males).
Fig. 11Respiration rate during fMRI scans across the sample.
Fig. 12Median framewise displacement across resting state scans (TR = 645/1400/2500 ms) and different filtering strategies (original results, lowpass at 0.1 Hz, lowpass at 0.31 Hz, and notch filter with a central frequency at 0.36 Hz and a width of 0.07 Hz).
| Measurement(s) | Cognition • Psychiatric Diagnosis • Development |
| Technology Type(s) | MRI • phenotypic battery • actigraphy • laboratory analysis |
| Sample Characteristic - Organism | Homo sapien |
| Sample Characteristic - Environment | Community-ascertained non-diagnostic sample |
| Sample Characteristic - Location | United States |